PROVIDENCE, RI – June 9, 2015 – The Defense Threat Reduction Agency (DTRA) is investing $5.2 Million for the development of a new type of vaccine against Q fever. Academic and industry organizations from around the world, led by Mark Poznansky of the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital and Annie De ...

We invite you to join us for this year’s iteration of the Computational Vaccinology Workshop @ ISV. Register for this event! Abstract submissions for full-length papers and posters are still being accepted – submit your abstracts now. The 5th Computational Vaccinology Workshop at International Society for Vaccines (CV5 @ ISV) is a satellite workshop to be held Saturday, October 17th ...

Anne De Groot, CEO of EpiVax, will testify before the Blue Ribbon Study Panel on Biodefense about encouraging innovative methods for solving existing and new biothreats. View a PDF of Annie’s testimony.

PROVIDENCE, R.I. – March 26, 2015 – The University of Rhode Island’s Institute for Immunology and Informatics is currently accepting fellows to participate in a workshop and training course targeting neglected tropical diseases (NTD) and emerging infectious diseases (EID). The workshop will focus on training NTD/EID researchers interested in using new vaccine design tools developed by Principal ...

UPDATE: April 28th, 2015. Here are the slides that EpiVax presented at the seminar: Vaccine Design Using in Silico Tools (6.4MB) Immunogenicity Screening and Epitope Engineering (6.3MB) We had a great time in Seoul and we hope you did also! Thank you for your participation and engagement. If you have any questions please email info@epivax.com for a prompt reply. We hope to ...

When two patients died* due to cardiac complications following treatment with an immunotherapy (T cells armed with a chimeric antigen receptor for a Mage A3 peptide), researchers checked the target peptide again. Using BLAST, there was no obvious cause: no cross-reactivity with any human protein was detected. But where BLAST failed, a new algorithm was able to clarify the relationship ...

Which one is not like the other? Why is one patient more likely to develop a side effect like anti-drug antibodies (ADA) than another? While there are many contributors to immunogenicity, most developers agree that T cell epitopes are key, and because they are, our genetic make up (HLA) determines who will, and who won’t ...

EpiVax Inc. enters license agreement with Novozymes Biopharma to advance pioneering treatment of autoimmune diseases Novozymes’ Veltis® albumin-based half-life extension platform will help move Tregitope treatment for autoimmune diseases closer to clinical development. Providence, RI. Monday December 22, 2014 EpiVax and Novozymes Biopharma today announced that they have entered a license agreement for the development of novel ...

Why is antigen-specificity key for biologics?  Annie De Groot, MD, CEO and CSO of EpiVax will be speaking at the CHI Immunogenicity summit on this topic, November 19th at 3 PM. It’s well known that tolerance can be induced by powerful transplant drugs but combining those powerful agents with biologics would not be generally acceptable (certainly not ...

GAIA Vaccine Foundation’s Story-Telling Cloth receives “Grand Challenges Explorations Grant” Award For West African-Style “Social Media” Cervical Cancer Prevention Campaign Providence, Rhode Island, 04 November 2014. The Bill and Melinda Gates Foundation awarded $100,000 to GAIA Vaccine Foundation to test whether dissemination of a printed cloth that tells the story of HPV, coupled with a media campaign ...

Providence, Rhode Island. October 30, 2014 Chugai Pharmaceutical Co. signed an agreement with Rhode Island-based biotechnology company, EpiVax, Inc., to incorporate EpiVax’s ISPRI immunogenicity screening and deimmunization technology into Chugai’s drug development toolbox. Chugai is widely regarded as one of the most cutting edge biopharmaceutical companies in Japan, Researchers at Chugai will be utilizing the cloud-based in ...

Ebola: It is better to Prevent than to Cure These days, every conversation starts with this question: Why don’t we have a vaccine against Ebola? Francis Collins, Director of the National Institutes of Health, gave the right answer in a recent interview: “Frankly, if ...

Senator Whitehouse (RI) addressed more than 100 experts in the field of vaccine development today at the 8th Vaccine Renaissance, an annual event organized by the University of Rhode Island’s Institute for Immunology and Informatics and supported by EpiVax. He stated that it was tragic that the Sequester achieved what it set out to do – to be a ...

Vaccine experts to gather in Providence as fight against deadly diseases carries on   Providence, R.I. – October 8, 2014 – As many African countries as well as the United States continue to grapple with the outbreak of Ebola and other deadly diseases, the University of Rhode Island is getting ready to play host to some of ...

For Immediate Release For Further Information: Media Spokesperson 401 272-2123 EpiVax,Inc. Info@EpiVax.com EpiVax CEO/CSO Annie De Groot MD named one of the 50 most influential people in Vaccines PROVIDENCE, R.I. – September 09, 2014 – EpiVax CEO and University of Rhode Island professor Annie De Groot M.D. has been named one of the most influential people in the vaccine industry by the national ...